Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study

Receptor‐interacting protein kinase 1 (RIPK1), a regulator of inflammation and cell death, is a potential therapeutic target in immune‐mediated inflammatory diseases (IMIDs). The objective of this phase IIa multicenter, randomized, double‐blind, placebo‐controlled study was to evaluate safety, toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Kathleen, Berger, Scott, Papp, Kim, Maari, Catherine, Krueger, James G., Scott, Nicola, Tompson, Debra, Wang, Susanne, Simeoni, Monica, Bertin, John, Peter Tak, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540322/
https://www.ncbi.nlm.nih.gov/pubmed/32301501
http://dx.doi.org/10.1002/cpt.1852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540322/
https://www.ncbi.nlm.nih.gov/pubmed/32301501
http://dx.doi.org/10.1002/cpt.1852

Ejemplares similares